Ariel Tevelev's Colleagues at IceCure Medical
Ariel Tevelev's Contact Details
901-316-5672
Israel
IceCure Medical
Ariel Tevelev's Company Details
SETTING NEW STANDARDS IN MINIMALLY-INVASIVE TUMOR THERAPYIceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for women's health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, IceCure's core technology is based on cryoablation, using freezing temperature (liquid nitrogen) to effectively destroy tumors safely, quickly, and painlessly, without the need for surgery.PROPRIETARY LIQUID NITROGEN TECHNOLOGY FOR MAXIMUM EFFICACY Based on liquid nitrogen, IceCure's proprietary third-generation technology generates lower tissue temperatures and a faster cooling rate than other methods, to enable a larger ice-ball tumor killing area for maximum efficacy. ENABLING IN-OFFICE TREATMENT OPTIONSCommercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South- Central America, its flagship system, ProSense™, uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The easy-to-use ProSense™ cryoablation procedure enables full physician control and can be performed in less than 30 minutes in the comfort of a doctor's office. As a proven solution for the treatment of fibroadenomas (benign breast tumors), the ProSense system is also indicated for use in the fields of general surgery, oncology, gynaecology and urology. CLINICAL SUPPORTProSense has been treating fibroadenomas (benign breast tumors) successfully since clinical trials began in 2012. The company is currently conducting the largest controlled multicenter clinical trial, ICE3, for freezing of small, low-risk, early-stage breast tumors with liquid nitrogen. PROVEN TEAM SUPPORTED BY WORLDWIDE EXPERTS IceCure's team leaders are seasoned medical device and technology entrepreneurs, who have teamed with world-renowned academics, clinical centers, and practitioners to establish advanced cryotherapy as the standard in oncology clinics worldwide.